Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (11): 19-28.doi: 10.6040/j.issn.1671-7554.0.2021.0603

Previous Articles     Next Articles

Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases

PANG Zhaofei1,2*, LIU Yong1*, ZHAO Xiaogang3, YAN Tao1, CHEN Xiaowei1, DU Jiajun1,4   

  1. 1. Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China;
    2. Department of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China;
    3. Department of Thoracic Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    4. Department of Thoracic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China
  • Published:2021-11-11

PDF (PC)

577

Abstract: Objective To predict immune checkpoint blockade(ICB)response in lung adenocarcinoma(LUAD)by identifying LUAD subtypes related to cancer stem cells and constructing a stemness-based scoring model. Methods LUAD RNA-seq data were obtained from TCGA database. By “limma” package, 329 differentially expressed genes(DEGs)related to cancer stem cells between LUAD(535 cases)and adjacent tissues(59 cases)were identified to classify LUAD into different subtypes(FDR<0.05, |log2 Fold Change|>2). By univariate Cox regression analysis, the common prognostic DEGs among different subtypes were further screened out. Using principal component analysis(PCA)and the 123 common prognostic DEGs, a stemness-based scoring model was established for 630 LUAD patients from TCGA and GEO. The cutoff value, determined by Kaplan-Meier curves analysis, was used to stratify LUAD patients into high- and low-score groups(cutoff value=-1.91). Furthermore, difference of distinct subtypes and stemness-based scores on tumor microenvironment(TME)and ICB therapy were analyzed. Results Thirty-six differentially expressed genes and three LUAD subtypes related to cancer stem cells(CSC-A, CSC-B, and CSC-C)were identified, overall survival rates of which were statistically different(P=0.033). The three subtypes greatly affected immune infiltration levels and were associated with multiple immune pathways, such as antigen presentation and cytotoxicity. A total of 123 common prognostic genes(P<0.05)were screened out to construct stemness-based scoring model by univariate Cox regression. In the low-score group, the infiltration of various immune cells and mRNA expressions of PD1, PD-L1 and CTLA4 were up-regulated. No matter anti-CTLA4 or anti-PD1 treatment alone, or combination of them, efficacy of the low-score group was better than that of the high-score group, and there was no significant difference in the efficacy of the two groups without ICB(P=0.060). In the anti-PD-L1 and anti-PD1 immunotherapy cohorts, the response rates of the low-score group were higher than that of the high-score group(the response rate of the anti-PD-L1 treatment cohorts: 50% vs 20%; the response rate of anti-PD1 treatment cohorts: 23% vs 0%). Conclusion Stemness-based scoring model has a potential to predict the efficacy of ICB therapy in LUAD patients, which is expected to provide a theoretical basis for ICB therapy in LUAD patients.

Key words: Cancer stemness, Immunotherapy, Lung adenocarcinoma, Tumor microenvironment, Immune checkpoint

CLC Number: 

  • R734.2
[1] Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma[J]. Cell Death Dis, 2018, 9(2):117.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[3] Zhao Z, Zheng L, Chen W, et al. Delivery strategies of cancer immunotherapy: recent advances and future perspectives[J]. J Hematol Oncol, 2019, 12(1): 126.
[4] Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558.
[5] Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723.
[6] Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell(CSC)resistance drivers[J]. Life Sci, 2019, 234: 116781. doi: 10.1016/j.lfs.2019.116781.
[7] Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications[J]. Annu Rev Pathol, 2016, 11: 47-76. doi: 10.1146/annurev-pathol-012615-044438.
[8] Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, et al. Cancer stem cell metabolism[J]. Breast Cancer Res, 2016, 18(1): 55.
[9] Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance[J]. Theranostics, 2020, 10(19): 8721-8743.
[10] Quaglino E, Conti L, Cavallo F. Breast cancer stem cell antigens as targets for immunotherapy[J]. Semin Immunol, 2020, 47: 101386. doi: 10.1016/j.smim.2020.101386.
[11] Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab[J]. Cell, 2017, 171(4): 934-949.e16.
[12] Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693): 544-548.
[13] Shi J, Hua X, Zhu B, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study[J]. PLoS Med, 2016, 13(12): e1002162.
[14] Spella M, Stathopoulos GT. Immune resistance in lung adenocarcinoma[J]. Cancers(Basel), 2021, 13(3): 384.
[15] Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor(Sintilimab)in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
[16] Clara JA, Monge C, Yang Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update[J]. Nat Rev Clin Oncol, 2020, 17(4): 204-232.
[17] Najafi M, Farhood B, Mortezaee K. Cancer stem cells(CSCs)in cancer progression and therapy[J]. J Cell Physiol, 2019, 234(6): 8381-8395.
[18] Raghavan S, Mehta P, Xie Y, et al. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments[J]. J Immunother Cancer, 2019, 7(1): 190.
[19] Miao Y, Yang H, Levorse J, et al. Adaptive immune resistance emerges from tumor-initiating stem cells[J]. Cell, 2019, 177(5): 1172-1186.e14.
[20] 王海洋, 董军. 靶向胶质瘤干细胞及其微环境的免疫治疗进展[J]. 中国现代神经疾病杂志, 2020, 20(2): 86-95. WANG Haiyang, DONG Jun. Immunotherapy targeting glioma stem cells and its microenvironment[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(2): 86-95.
[21] Hinshaw DC, Shevde LA. The Tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
[22] Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application[J]. J Hematol Oncol, 2017, 10(1): 58.
[23] Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557-4566.
[24] 马冉冉, 韩琛, 王朝霞, 等. 人参总皂苷调控NK细胞活性促进5-氟尿嘧啶抗肿瘤的作用[J]. 山东大学学报(医学版), 2018, 56(4): 43-50. MA Ranran, HAN Chen, WANG Zhaoxia, et al. Total saponins of Panax ginseng promoting the anticancer activity of 5-Fluorouracil by mediating NK cell activity[J]. Journal of Shandong University(Health Sciences), 2018, 56(4): 43-50.
[25] Kurachi M. CD8 T cell exhaustion[J]. Semin Immunopathol, 2019, 41(3): 327-337.
[26] Zhang B, Chikuma S, Hori S, et al. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model[J]. Proc Natl Acad Sci U S A, 2016, 113(30): 8490-8495.
[27] Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update[J]. Immunotherapy, 2016, 8(3): 279-298.
[28] Bassi R, Fornoni A, Doria A, et al. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease[J]. Diabetologia, 2016, 59(1): 21-29.
[29] Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nature reviews Cancer, 2016, 16(5): 275-287.
[30] Walk EE, Yohe SL, Beckman A, et al. The cancer immunotherapy biomarker testing landscape[J]. Arch Pathol Lab Med, 2020, 144(6): 706-724.
[31] Liu JN, Kong XS, Huang T, et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study[J]. Front Immunol, 2020, 11: 2048. doi: 10.3389/fimmu.2020.02048.
[1] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[2] ZHENG Haotian, WANG Guanghui, ZHAO Xiaogang, WANG Yadong, ZENG Yukai, DU Jiajun. A prognostic risk model for LKB1 mutant lung adenocarcinoma based on aberrant DNA methylation sites [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 51-58.
[3] GAO Huijiang, WEI Yucheng. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[4] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[5] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[6] CHAI Xiaoxue, YE Hui, LYU Xinran, DING Xuchao, ZHEN Qiulai, DU Juan, CAO Lili. Prognostic value of POU4F3 in 118 patients with lung adenocarcinoma and its effect on migration of lung adenocarcinoma cells [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 8-18.
[7] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[8] YANG Xiuting, LIU Qigong, ZUO Ping, LIU Zhengxiang, ZUO Houjuan. Effect of CD151-MUT mutation on migration of lung adenocarcinoma cell line A549 and its mechanism [J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 81-86.
[9] WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20.
[10] HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5.
[11] WANG Zhao. Advances in the clinical treatment of hemophagocytic lymphohistiocytosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 44-49.
[12] ZHENG Qingyue, ZHAO Qiuhong, QU Xiangyun, DONG Zhaonan, MA Xueqing, JIA Yunli. Diagnosis value of serum exosome miR-205-5p/miR-152-5p on early non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 101-106.
[13] XIE Hounai, LI Meng, XU Lin, WANG Hui, PENG Yue, PENG Zhongmin. Clinical analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-ⅢA lung adenocarcinoma harbouring positive EGFR mutations [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 29-34.
[14] JIANG Yunfeng, DONG Xiaopeng, ZHAO Xiaogang. Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 11-16.
[15] ZHANG Zhihui, WANG Lili, GAO Hua, ZHANG Jian, LI Juan, LI Yuan, WU Chunxiao, LU Zhiming. Role of hypoxia-inducible factor-1α in the regulation of programmed death ligand 1 expression in lung adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 65-70.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] GAO Jing,CHEN Wen,ZHANG Tong-xia,WANG Xiao-hua,DAI Ting-jun,YAO Hong,ZHAO Xiu-he,CHI Zhao-fu,SHAN Pei-yan. Changes of expression of mitochondrial cytochrome oxidase subunits Ⅲ and Ⅳ in the rat hippocampus of temporal lobe epilepsy[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(8): 817 -820 .
[2] XIAO Wei-ling,LIN Ya-jie,MU Dong-zhen,SUN Ping,LIANG Shu-juan. Recombinational expression of classical pathway secreted human IL-1β in hepatoma H7402 cells[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(2): 119 -122 .
[3] . Expression and significance of stem cell marker LGR5 proteins in the  development  and progression of human colorectal carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(8): 85 -88 .
[4] YU Yuan1, LI Yan1, RONG Fengnian2, LIANG Jing1, LIU Xiaolin1, WANG Fuli1. Therapy effect of auto-CIK on regulatory T cells in ovarian neoplasms patients[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(5): 101 -104 .
[5] LIN Wen-li1， ZHANG Nan2， QU Fei3， LIU Jie2， WANG Jing-nan4， XIE Tian-yan3, SUN Yu-ping2. Co-expression of hepatocyte growth factor and vascular endothelial growth factor-c in non-small cell lung cancer and their relationship  with lymphangiogenesis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(10): 111 -115 .
[6] LIU Yimin, DU Lutao, WANG Lili, JIANG Xiumei, LI Juan, QU Ailin, WANG Haiyan, ZHENG Guixi, ZHANG Xin,YANG Yongmei, WANG Chuanxin. Identification and validation of suitable reference genes for the investigation of serum microRNA in bladder cancer patients[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 86 -91 .
[7] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(7): 751 -752 .
[8] ZHANG Yuan-kai, LIU Pei-lai, LI De-qiang, LI Ming. Application of axial laminar screws combined with atlantal lateralmass screws fixing   method in the surgery of complicated atlantoaxial dislocation[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(11): 98 .
[9] TANG Hai-rong, YUAN Bin-bin, HU Da-yi, Buaijiaer·Hasimu. Prediction of ankle-brachial index to all-cause and cardiovascular mortalities in patients with high cardiovascular risk[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(1): 53 .
[10] FU Kai-li1, ZHANG Xue-yi2, ZHU Meng3, WANG Zhi-hao1, WANG Hua1, ZHONG Ming1, ZHANG Yun1, ZHANG Wei1. Evaluation of stroke risks in patients with atrial fibrillation due to different pathogenesis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 61 -63 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd